非甾体抗炎药物局部点眼辅助治疗AMD研究进展

doi:10.3760/cma.j.issn.1674-845X.2015.02.017

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (658 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Intravitreous injection of vascular endothelial growth factor （VEGF） inhibition is the main method of wet age-related macular degeneration （AMD） treatment. The biggest drawback of this regimen is the high cost， which make poor people lose the treatment opportunity， and repeated drug injection， which increases the incidence of a lot of complications. Therefore， how to decrease the number of drug administration is the most urgent problem to solve. Non-steroidal anti-inflammatory drugs （NSAID） have the anti-inflammation and anti-angiogenesis effects. Previous studies have shown that NSAID as an adjunctive therapy of anti-VEGF drugs for AMD can improve the treatment effect， reduce the times of intravitreous injection of VEGF drugs， and reduce the central macular thickness. Thus， the mechanism of NSAID for CNV treatment and related progress in animal experiments and clinical trials were reviewed in this paper， in order to raise concerns of more ophthalmologist about this auxiliary treatment and to promote further researches.

Key words： Age-related macular degeneration Nonsteroidal anti-inflammatory drugs Bromfenac Nepafenac Vascular endothelial growth factor

Corresponding Authors: Du Junhui， Email： djh79918@163.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Du Junhui
	Li Rong

Cite this article:

Du Junhui,Li Rong. Progress in the study of nonsteroidal anti-inflammatory drugs as an adjunctive therapy for wet age-related macular degeneration[J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2015, 17(2): 122-125.

URL:

https://www.cjoovs.com/EN/10.3760/cma.j.issn.1674-845X.2015.02.017 OR https://www.cjoovs.com/EN/Y2015/V17/I2/122

[1]	中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会. 中国老年性黄斑变性临床诊断治疗路径[J]. 中华眼底病杂志，2013，29（4）：343-355.
[2]	黎晓新. 普及推广“中国老年性黄斑变性临床诊断治疗路径”，规范老年性黄斑变性的诊断治疗[J]. 中华眼底病杂志，2013， 29（4）：341-342.
[3]	Wu L， Martinez-Castellanos MA， Quiroz-Mercado H， et al. Twelve-month safety of intravitreal injections of bevacizumab （Avastin）： results of the Pan-American Collaborative Retina Study Group （PACORES）[J]. Graefes Arch Clin Exp Ophthalmol，2008，246（1）：81-87.
[4]	Jonas JB， Libondi T. Study on the potential benefit of adding topical bromfenac to intravitreal injections of ranibizumab for the therapy of exudative age-related macular degeneration[J]. Retina，2013，33（5）：1093.
[5]	Gomi F， Sawa M， Tsujikawa M， et al. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration[J]. Retina，2012，32（9）：1804-1810.
[6]	Flaxel C， Schain MB， Hamon SC， et al. Prospective randomized controlled trial of combination ranibizumab （Lucentis） and bromfenac （Xibrom） for neovascular age-related macular degeneration： a pilot study[J]. Retina，2012，32（3）：417-423.
[7]	艾明，杨芳，李岱. 脉络膜新生血管形成机制的研究进展[J]. 临床眼科杂志，2011，19（4）：372-374.
[8]	刘晓娟. 玻璃体腔注射bevacizumab的并发症[J]. 眼科研究，2010，28（6）：571-575.
[9]	Kahook MY， Kimura AE， Wong LJ， et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections[J]. Ophthalmic Surg Lasers Imaging，2009，40（3：293-295.
[10]	Querques G. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction[J]. Am J Ophthalmol，2009，147（2）：375-376，376-377.
[11]	van Wijngaarden P， Qureshi SH. Inhibitors of vascular endothelial growth factor （VEGF） in the management of neovascular age-related macular degeneration： a review of current practice[J]. Clin Exp Optom，2008，91（5）：427-437.
[12]	王静波，关娟，周历，等. 玻璃体腔注射抗血管内皮生长因子药物治疗年龄相关性黄斑变性引起的视网膜色素上皮撕裂的特点分析[J]. 中华眼视光学与视觉科学杂志，2010，12（5）：378-381.
[13]	Hohman TC. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases[J]. Retina，2009，29（6 Suppl）：S51-S53.
[14]	Afzal A， Shaw LC， Ljubimov AV， et al. Retinal and choroidal microangiopathies： therapeutic opportunities[J]. Microvasc Res，2007，74（2-3）：131-144.
[15]	杜军辉，王雨生，李蓉. 眼局部应用非甾体类抗炎药的研究进展[J]. 临床眼科杂志，2009，17（3）：284-287.
[16]	Radi ZA， Render JA. The pathophysiologic role of cyclo-oxygenases in the eye[J]. J Ocul Pharmacol Ther，2008，24（2）：141-151.
[17]	蔡岩，王雨生. 环氧化酶-2与脉络膜新生血管[J]. 眼科研究，2010，28（1）：86-89.
[18]	Rezaei KA， Toma HS， Cai J， et al. Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice[J]. Invest Ophthalmol Vis Sci，2011，52（2）：701-707.
[19]	Kuwano T， Nakao S， Yamamoto H， et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis[J]. FASEB J，2004，18（2）：300-310.
[20]	Kim SJ， Flach AJ， Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology[J]. Surv Ophthalmol，2010，55（2）：108-133.
[21]	李娟娟，张美霞. Rac1-siRNA抑制大鼠视网膜NF-кB表达的实验研究[J]. 眼科新进展，2008，28（9）：646-648.
[22]	Jones MK， Szabo IL， Kawanaka H， et al. von Hippel Lindau tumor suppressor and HIF-1alpha： new targets of NSAIDs inhibition of hypoxia-induced angiogenesis[J]. FASEB J，2002， 16（2）：264-266.
[23]	Yoshinaga N， Arimura N， Otsuka H， et al. NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway[J]. Lab Invest，2011，91（9）：1277-1290.
[24]	Tatar O， Yoeruek E， Szurman P， et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization[J]. Arch Ophthalmol，2008，126（6）：782-790.
[25]	Waterbury LD， Silliman D， Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium[J]. Curr Med Res Opin，2006，22（6）：1133-1140.
[26]	Baklayan GA， Patterson HM， Song CK， et al. 24-hour evaluation of the ocular distribution of （14） C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits[J]. J Ocul Pharmacol Ther，2008，24（4）：392-398.
[27]	Zweifel SA， Engelbert M， Khan S， et al. Retrospective review of the efficacy of topical bromfenac （0.09%） as an adjunctive therapy for patients with neovascular age-related macular degeneration[J]. Retina，2009，29（10）：1527-1531.
[28]	Stewart RH， Grillone LR， Shiffman ML， et al. The systemic safety of bromfenac ophthalmic solution 0.09%[J]. J Ocul Pharmacol Ther，2007，23（6）：601-612.
[29]	Jones J， Francis P. Ophthalmic utility of topical bromfenac， a twice-daily nonsteroidal anti-inflammatory agent[J]. Expert Opin Pharmacother，2009，10（4）：2379-2385.
[30]	Takahashi K， Saishin Y， Saishin Y， et al. Topical nepafenac inhibits ocular neovascularization[J]. Invest Ophthalmol Vis Sci，2003，44（1）：409-415.
[31]	Yanni SE， Clark ML， Yang R， et al. The effects of nepafenac and amfenac on retinal angiogenesis[J]. Brain Res Bull，2010， 81（2-3）：310-319.
[32]	Libondi T， Jonas JB. Topical nepafenac for treatment of exudative age-related macular degeneration[J]. Acta Ophthalmol，2010，88（2）：e32-e33.
[33]	Chen E， Benz MS， Fish RH， et al. Use of nepafenac （Nevanac） in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections[J]. Clin Ophthalmol，2010，4：1249-1252.
[34]	Kern TS， Miller CM， Du Y， et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology[J]. Diabetes，2007，56（2）：373-379.